Although these studies utilizing RIPK2 inhibitors have not clearly shown whether such small molecules suppressed the activity of the NOD2–RIPK2 and TLRs–RIPK2 pathways to improve inflammation, their therapeutic and preventive effects seen in experimental IBD allow considering RIPK2 as a new therapeutic target in human IBD. The gene discussed is NOD2; the disease is inflammatory bowel disease.